IR Overview

Executive Team

  • Adrian  Rawcliffe

    Adrian Rawcliffe

    Chief Executive Officer

    Adrian Rawcliffe has served as our Chief Executive Officer since September 2019. Previously, he served as our Chief Financial Officer from March 2015 through September 2019.

    Mr. Rawcliffe has over 20 years of experience within the biopharmaceutical industry and most recently served as Senior Vice President, Finance of GSK’s North American Pharmaceuticals business. He joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK’s Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK’s venture capital business. Mr. Rawcliffe currently serves as a non executive director of WAVE Life Sciences (NASDAQ: WVE).

    Mr. Rawcliffe qualified as a chartered accountant with PwC and holds a B.Sc. degree in Natural Sciences from the University of Durham, U.K.

  • Michael (Mike) Garone

    Michael (Mike) Garone

    Interim Chief Financial Officer

    Mike Garone has served as our Interim Chief Financial Officer since October 2019.

    Mr. Garone has over 30 years of experience in corporate finance, accounting and risk management in telecommunications and biopharmaceuticals industries. From June 2016 through August 2018, he served as Vice President, Finance, and Chief Financial Officer of Immunomedics, Inc., an innovative biopharmaceutical company that focuses on novel immunotherapeutics for the treatment of cancer, autoimmune and other serious diseases, where he also served as interim Chief Executive Officer from July through December 2017. Previously, Mr. Garone served as Chief Financial Officer of Emisphere Technologies, Inc., a commercial stage, specialty pharmaceutical company, from August 2007 through June 2016 and as Interim Chief Executive Officer from February 2011 through September 2012. Before Emisphere, Mr. Garone served as Interim Chief Executive Officer and Chief Financial Officer of Astralis, Ltd. Prior to that, he served for 20 years at AT&T, where he held several positions, including Chief Financial Officer of AT&T Alascom.

    Mr. Garone received an MBA from Columbia University and a BA in Mathematics, and Philosophy and Religion from Colgate University.

  • Helen

    Helen Tayton-Martin PhD, MBA

    Chief Business Officer

    Dr. Helen Tayton-Martin has served as our Chief Business Officer since March 2017, having formerly served as our Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO.

    As our CBO, Dr. Tayton-Martin is responsible for optimizing the strategic and commercial opportunity for Adaptimmune’s assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company’s strategic partnership with GlaxoSmithKline (LSE/NYSE: GSK) (“GSK”).

    Dr. Tayton‑Martin has over 26 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co‑founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008.

    Dr. Tayton‑Martin also serves as a non‑executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.

  • William (Bill) Bertrand

    William (Bill) Bertrand

    Chief Operating Officer

    William (Bill) Bertrand has served as our Chief Operating Officer since March 2017 and is responsible for operational functions including compliance, risk management, human resources, quality and legal/IP, as well as investor relations, communications and IT and facilities.

    Mr. Bertrand’s prior experience includes a 12 year tenure at MedImmune, where he served as its first General Counsel and Chief Compliance Officer, along with holding a variety of operational and corporate strategy roles. He has also formerly served as Executive Vice President, General Counsel for Infinity Pharmaceuticals, Inc., and as Senior Vice President, Acting Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize the integration of the company’s $14 billion acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx, Inc. (NASDAQ: ARDX) and has served as a member of the board of directors of several private companies including Trustwave and Inotek Pharmaceuticals. Mr. Bertrand received a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State University.

  • John Lunger

    John Lunger

    Chief Patient Supply Officer

    John Lunger has served as our Chief Patient Supply Officer since August 2019. John leads the teams responsible for producing and delivering products to patients, accelerating supply execution, and optimizing the supply chain to be ready for commercialization. Prior to joining our Executive Team, he was Senior Vice President, Manufacturing and Supply Chain at Adaptimmune, having joined the Company in March of 2017. In this role, he was responsible for clinical manufacturing and global supply of Adaptimmune’s autologous T-cell therapy products.

    Previously, John was Head of Supply Chain and Commercial Product Supply at Merrimack Pharmaceuticals where he led clinical and commercial supply chain as well as the cross functional supply team for Merrimack’s first commercial product launched in October of 2015. Earlier in his career, he held various senior manufacturing, operational, and strategy roles with VWR International, Pfizer, and Wyeth Pharmaceuticals. In his nearly 10 years with Wyeth he held a number of leadership positions, including operations and supply chain strategy, supply management, procurement and strategic sourcing, business systems implementation, generic pharmaceutical business management, and site operations management in a pharmaceutical manufacturing plant in Ireland. John began his career serving as a nuclear trained officer on a U.S. Navy submarine followed by strategic consulting with Accenture.

    John holds a Bachelor of Science degree (with distinction) in Ocean Engineering from the U.S. Naval Academy and an MBA in economics and operations management from the University of Chicago’s Booth School of Business.